| 摘要 |
PURPOSE: A sustained release formulation containing solid dispersion containing polyvinyl pyrrolidone(PVP) and sustained release substrate is provided to improve mosapride release and to enhance bioavailability. CONSTITUTION: A sustained release formulation contains a solid dispersion containing mosapride, polyvinylpyrrolidone(PVP) and sustained release polymers in a ratio of 1:3:1-3. The sustained release polymer is EUDRAGIT RS PO, EUDRAGIT RL PO, hydroxypropyl methylcellulose(HPMC), or KOLLIDON SR. The solid dispersion is prepared by dissolving mosapride, PVP, and sustained release polymers in alcohol and evaporating at 30-50°C. The sustained release formulation is a tablet for oral administration. |
